Choice of Posterpresentations with Pegaspargase

1608 Premedication Prior to Peg-Asparaginase Is Cost-Effective for Pediatric Leukemia Patients

Meghan McCormick, Jillian Lapinski, Erika Friehling, and Ken Smith WEBCAST (ASH-registration required)

Conclusion: Compared to other strategies, premedication use and asparaginase level monitoring in children with ALL is economically reasonable and potentially cost-saving.

1885 Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells

Quentin Fovez, Raeeka Khamari, Anne Trinh,et al. WEBCAST (ASH-registration required)

Conclusion: Persistent leukemia cells that survive after exposure to FLT3 inhibitor quizartinib can be targeted by the clinical drug L-asparaginases. This metabolic strategy could reduce the emergence of leukemic cells resistant to quizartinib.

1900 Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase

Catherine Hughes, Valeria Bernardo, Susanne Youssef, et al. WEBCAST (ASH-registration required)

Conclusion: Premedication with antihistamines and corticosteroids or prolongation of infusion time did not affect the incidence of hypersensitivity reactions to PEG over a three-year period at our institution. The rate of silent inactivation was extremely low and did not increase after premedication was instituted. These results contrast with prior single institution reports regarding reductions in hypersensitivity reactions and indicate that larger, multi-center trials are needed to determine the efficacy of premedication or prolongation of infusion time on reducing hypersensitivity reactions to PEG during pediatric ALL therapy.

2074 Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Qingqing Cai, Huiqiang Huang,  Panpan Liu, et al. WEBCAST (ASH-registration required)

Conclusion: Sintilimab plus P-GEMOX regimen demonstrated manageable safety profile and promising anti-tumor activity in pts with untreated advanced ENKTL. The preliminary safety and efficacy profile of combination therapy support further study and the exploration of effective biomarkers for predicting the treatment response is under way.

2833 Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, Elias Jabbour, Nitin Jai, et al. WEBCAST (ASH-registration required)

Conclusion: HCVAD with NEL with or without PEG is safe and effective as frontline therapy of adults with newly diagnosed T-ALL/LBL. Addition of PEG appears to confer a benefit.